Search
Varicella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalFurthermore, because Shingrix is an inactivated vaccine it can also be used to prevent shingles and PHN in individuals with suppressed immune systems, who are already at increased risk of developing shingles … Person's living with HIV or cancer, those taking immunosuppressants, and transplant recipients are particularly at risk [L1037].
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalIt was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. … It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexIoversol
go.drugbank.com/drugs/DB09134ApprovedInvestigationalIoversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. … [L41780] Iodine has a high atomic density, which gives it the ability to attenuate X-rays.
Categories: Compounds used in a research, industrial, or household settingSutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawnSutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder. … Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation.
Romosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalRomosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant … In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months
Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexUric acid
go.drugbank.com/drugs/DB08844InvestigationalAt present (August 2013), there is no approved formulation or indication for uric acid. … As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant.
Categories: Compounds used in a research, industrial, or household settingArnica montana flower
go.drugbank.com/drugs/DB14343ApprovedArnica montana flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: . - GelVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … [L48216] α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization of lymphocytes and thus contributing
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnAs a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting … Tropisetron is an indole derivative with antiemetic activity.